Hybrisens Limited
North York, ON
Company Overview
Early Stage Company with Platform Technology
Purpose:
To develop new versions of proven protein drugs, with reduce adverse side effects and better clinical utility.
Platform Technology:
Patented molecular configuration for creating"Chimeric" protein - drugs - proven protein therapeutics genetically fused to naturally induced immuno-protective molecules which resist elimination from the blood. This extends the drug's Half-life by several orders of magnitude, improves its effectiveness, and reduces toxicity.
Patents:
Issued in the U. S., Canada, Britain and the Commonwealth, the European Community; pending in Japan.
Products:
Under development, chimeric versions of interleukin (IL-2, IL-6).
Disease Indications:
Renal cell (Kidney) carcinoma, melanoma (skin) cancer, AIDS.
Financial:
Founded in 1986, the company has maintained profitability over the last four years through income from contract R&D for academic institutions and pharmaceutical companies.
Management:
Experienced management team supported by distinguished scientific advisers.
Facilities:
Well equipped and fully supported laboratory, located at York University campus.
Ownership:
Private, with the following as major shareholders:
Innovation Ontario - a provincial crown corporation - 35% MABS - Small Business Development Corporation - 28% Current and former management and employees - 37%
KEY POINTS
- Platforms technology, with established"proof-of-principle"
and core patent in over 20 countries.
- Experienced management team with proven track record of
maintaining profitability.
- Well-defined, potential market for cancer therapeutic the first
two indications mentioned above currently estimated at U$ 580, 000, 000.
- Products entering final stages of preclinical development.
- Established growth strategy and business plan, with clear
targets for completing preclinical-phase for chimeric-IL-2 within two years.
- Potential to increase shareholders value significantly in the
near future.
Company Information
Physical Address
York University Keele St. Campus, 124 Farquarson Bldg.
North York, ON M3J 1P3
CA
Mailing Address
York University Keele St. Campus, 124 Farquarson Bldg.
North York, ON M3J 1P3
CA
Additional Details
Legal Name: Hybrisens Limited
Number of Employees: 5
CA
Contacts
Services
- Biotechnology
Products
- Early Stage Company With Platform Technology
-
Interleukin (il-2, Il-6).
Product under development, chimeric versions of interleukin (IL-2, IL-6).
NAICS Categories
Additional Information
541710, 611310